Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 47,709 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 47,709 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $25.04, for a total transaction of $1,194,633.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total transaction of $210,720.00.
• On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.69, for a total transaction of $188,280.00.

Enliven Therapeutics Stock Down 6.3 %

Shares of NASDAQ:ELVN opened at $18.69 on Wednesday. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The stock has a market capitalization of $770.03 million, a P/E ratio of -8.53 and a beta of 1.06. The firm has a fifty day simple moving average of $16.94 and a two-hundred day simple moving average of $14.29.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the 3rd quarter valued at about $157,000. China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics during the 4th quarter valued at about $66,000. Exchange Traded Concepts LLC lifted its holdings in Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after buying an additional 2,208 shares in the last quarter. Bank of America Corp DE bought a new stake in Enliven Therapeutics during the 1st quarter valued at about $143,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics during the 4th quarter valued at about $140,000. Institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Mizuho began coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.